Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 42675

Drug Profile

EP 42675

Alternative Names: EP42675; Org 42675

Latest Information Update: 02 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Endotis Pharma
  • Class Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 06 Dec 2009 Pharmacokinetics, pharmacodynamics and drug interactions data from two phase I trials in Healthy volunteers presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
  • 19 May 2009 Adverse events data from phase I trials in healthy subjects released by Endotis Pharma
  • 19 May 2009 Endotis Pharma completes its phase I programme in Thrombosis in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top